NR2F6 and neoplasm: (6) found that the knockout of NR2F6 enhanced the activity of an established programmed death-ligand 1 (PD-L1) checkpoint blockade, thereby promoting tumor regression, and increasing the survival rate of the subcutaneous tumor model.